Delve Health

Enrollment isn't adoption. A wearable on the wrist ≠ one worn correctly, charged, and synced. When patients drift, it shows up in your endpoints, not your enrollment numbers. The tech is the easy part. Keeping patients using it right is the work.

Wearable data in clinical trials: Everyone's talking about collection. Nobody's talking about what happens when the signal doesn't translate into usable, study-ready data. Deployment isn't execution. That gap is where endpoints break down.

Clinical trials have more tech, more tools, and more data than ever. So why do patient retention, compliance, and patient experience still break down? #ClinicalTrials #PatientRetention #ClinicalResearch #PatientEngagement #DigitalHealth #Pharma #Biotech

We made the list! 🏆 Delve Health is proud to be named one of the fastest-growing private companies in the Midwest by @Inc! 🚀 It’s been an incredible 2 years of growth in the #HealthTech space. #IncRegionals #ClinicalTrials #DigitalHealth #Growth

Clinical trial patient goes quiet in Week 3. No diary entries. Wearable unsynced. At risk of dropping out. Delve Health concierge calls him. On the phone. Right then. Diary completion: 91% Retention: 96% Human support = study integrity. #ClinicalTrials #DelveHealth

Same patient. Same trial. One difference: someone actually helps. Not reminders. Not dashboards. A real person. That’s when compliance starts to recover. Episode 2 of 3. #ClinicalTrials #PatientEngagement #DigitalHealth

Clinical trials don’t fail at visits. They fail between them. No support → confusion → missed data → dropout. Compliance doesn’t crash— it erodes. Episode 1 of 3. #ClinicalTrials #PatientCompliance #DigitalHealth

Vaccine trials are global. Execution still assumes perfect connectivity. That’s why data gets lost. Offline gaps. Rural patients. Missed syncs. If patients can’t stay connected, your dataset won’t stay complete. #WVC #VACCINE #ClinicalTrials #Biotech #Pharma

Clinical trials are not just more digital. They are more operationally complex. More endpoints. More vendors. More longitudinal data. Execution continuity — not technology — will define usable evidence. #ClinicalTrials #PMCF #RWE #MedTech

AI can predict adherence risk. It cannot sustain execution discipline. Long-duration trials degrade quietly. Post-approval evidence quality increasingly depends on continuity ownership, not instrumentation. #ClinicalTrials #AIinHealthcare #RWE #DigitalHealth

Clinical trials are failing because of poor execution between visits. As trials grow, retention, adherence, and data continuity become structural risks. Protocol complexity already impacts outcomes: pmc.ncbi.nlm.nih.gov/articles/PMC93… The next evolution in trials = execution discipline.

As trials grow more digital, fragmented outcome capture creates real execution risk. eCOA, engagement, and data oversight must work as one system — not separate vendors. That’s where study performance is shaped. delvehealth.com/ecoa.html

Tired of low eCOA completion? Delve Health delivers 92–98% completion with real-time QC, wearables integration, & human concierge support. Unified eCOA/ePRO for cleaner data & faster readouts. Check it out: delvehealth.com/ecoa.html #eCOA #ClinicalTrials #DigitalHealth

CNS trials capture neuro diseases only on clinic days. Alz & PD fluctuate daily. 2026: ~940 CNS drugs in trials, Phase 2/3 fails ~85-90%. True progression or clinic snapshots? Wearables catch between-visit signals. Bridging the gap? 👇 delvehealth.com/cns.html #CNSClinicalTrials

Alzheimer’s, Parkinson’s, and MS studies depend on data collected between visits. That’s why modern CNS clinical trials rely on wearables, digital biomarkers, and eCOA to protect the signal. delvehealth.com/cns.html #CNSResearch #ClinicalTrials

Most psoriasis and atopic dermatitis clinical trials focus on what happens in clinic. But the real variability builds at home.

Behavior affects endpoints in dermatology clinical trials. Topical adherence. PRO completion. Photo documentation. Visit attendance. Derm trials need structured compliance infrastructure. delvehealth.com/derm.html #Dermatology #ClinicalResearch

Vendor fragmentation increases risk in dermatology clinical trials. eCOA. Photo capture. Central reading. Wearables. Reminder systems. Disconnected systems = operational variability. Integrated dermatology trial infrastructure: delvehealth.com/derm.html #ClinicalTrials #Dermatology

Dermatology clinical trials are visit-based. Psoriasis & atopic derm are not. Between visits: • Topical adherence fluctuates • Flares evolve • Sleep disruption increases • PRO variability grows delvehealth.com/derm.html #DermatologyClinicalTrials #Psoriasis #AtopicDermatitis

Rare disease trials have no operational cushion. When enrollment is 30–60 patients, small gaps become endpoint risks. Proactive concierge isn’t support. It’s protection. #RareDisease #ClinicalTrials Learn more: delvehealth.com/rare-disease.h…